ES2150906T3 - Antigeno del virus varicella-zoster. - Google Patents

Antigeno del virus varicella-zoster.

Info

Publication number
ES2150906T3
ES2150906T3 ES91919890T ES91919890T ES2150906T3 ES 2150906 T3 ES2150906 T3 ES 2150906T3 ES 91919890 T ES91919890 T ES 91919890T ES 91919890 T ES91919890 T ES 91919890T ES 2150906 T3 ES2150906 T3 ES 2150906T3
Authority
ES
Spain
Prior art keywords
tgp
present
secretora
varicella
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91919890T
Other languages
English (en)
Inventor
Abbas Vafai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Corp Technologies Inc
Original Assignee
Research Corp Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Corp Technologies Inc filed Critical Research Corp Technologies Inc
Application granted granted Critical
Publication of ES2150906T3 publication Critical patent/ES2150906T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/12—Acyclic radicals, not substituted by cyclic structures attached to a nitrogen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C07K16/088—Varicella-zoster virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

LA PRESENTE INVENCION ESTA RELACIONADA CON LA CONSTRUCCION DE UN PLASMIDO RECOMBINANTE QUE SEA CAPAZ DE EXPRESAR UNA GLUCOPROTEINA TRUNCADA SECRETORA (TGP) DEL VIRUS VARICELLA-ZOSTER (BZV) EN CELULAS DE MAMIFEROS. LA TGP SECRETORA DE LA PRESENTE INVENCION CONTIENE, AL MENOS, UN EPITOPE CAPAZ DE INDUCIR RESPUESTA DE ANTICUERPOS, LA PRESENTE INVENCION CONTEMPLA LA PRODUCCION Y UTILIZACION DE ESTA TGP SECRETORA EN UNA VACUNA CONTRA LA VARICELA Y/O EL HERPES ZOSTER. LA PRESENTE INVENCION TAMBIEN SE DIRIGE AL USO DE LA TGP SECRETORA EN ANALISIS DE DIAGNOSTICO PARA LA DETECCION DEL VZV. LA PRESENTE INVENCION TAMBIEN SE DIRIGE A LOS PRIMEROS ANTICUERPOS ESPECIFICOS DE LA TGP SECRETORA Y A LOS SEGUNDOS ANTICUERPOS ESPECIFICOS DE LOS PRIMEROS ANTICUERPOS. ESTOS SEGUNDOS ANTICUERPOS TAMBIEN SON UTILES EN LOS ANALISIS DE DIAGNOSTICO DEL VZV.
ES91919890T 1990-10-04 1991-10-04 Antigeno del virus varicella-zoster. Expired - Lifetime ES2150906T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US59276690A 1990-10-04 1990-10-04

Publications (1)

Publication Number Publication Date
ES2150906T3 true ES2150906T3 (es) 2000-12-16

Family

ID=24371982

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91919890T Expired - Lifetime ES2150906T3 (es) 1990-10-04 1991-10-04 Antigeno del virus varicella-zoster.

Country Status (10)

Country Link
US (1) US6180369B1 (es)
EP (1) EP0504388B1 (es)
JP (1) JP3990445B2 (es)
KR (1) KR920703614A (es)
AT (1) ATE196163T1 (es)
CA (1) CA2068654C (es)
DE (1) DE69132404T2 (es)
DK (1) DK0504388T3 (es)
ES (1) ES2150906T3 (es)
WO (1) WO1992006989A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE210722T1 (de) 1992-07-17 2001-12-15 Merck & Co Inc Methode zur verhinderung von zoster und linderung der mit varicellea verbundenen postherpetischen neuralgie
GB9413751D0 (en) * 1994-07-07 1994-08-24 British Bio Technology Immunodominant peptides
KR970006484A (ko) * 1995-07-27 1997-02-21 수두 바이러스의 당단백질을 대량발현시키는 동물세포주
US6528066B1 (en) * 1999-09-14 2003-03-04 University Of Iowa Research Foundation Variant varicella-zoster viruses and methods of use
EA202092828A1 (ru) * 2018-05-23 2021-03-11 Могам Инститьют Фор Байомедикал Рисерч Антигенный вариант вируса varicella zoster и его применение
CN112941031B (zh) * 2021-02-20 2023-06-27 安徽智飞龙科马生物制药有限公司 一种gE-HEK293细胞的构建方法及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4008317A (en) 1975-12-29 1977-02-15 Recherche Et Industrie Therapeutiques (R.I.T.) Varicella-zoster virus vaccine and preparation thereof
DE2930706A1 (de) 1979-07-28 1981-02-05 Medac Klinische Spezialpraep Verfahren zum nachweis von erregerspezifischen antikoerpern
US4663277A (en) 1983-05-20 1987-05-05 Profile Diagnostic Sciences Inc. Virus detection method and materials
DE3587991T2 (de) 1984-04-06 1995-07-20 Chiron Corp Rekombinanter herpes simplex gb-gd impfstoff.
US4769239A (en) 1984-08-21 1988-09-06 Merck & Co., Inc. Vaccine against varicella-zoster virus
US4686101A (en) 1985-08-02 1987-08-11 Merck & Co., Inc. Vaccine against varicella-zoster virus
JPH01252279A (ja) 1988-03-31 1989-10-06 Chemo Sero Therapeut Res Inst 帯状疱疹ウイルス糖蛋白質およびその製法
CY1933A (en) 1989-06-27 1990-06-22 Smithkline Biolog Novel compounds
EP0406857B1 (en) * 1989-07-07 1995-05-24 Takeda Chemical Industries, Ltd. Proteins and production thereof
JPH03232897A (ja) * 1989-11-16 1991-10-16 Takeda Chem Ind Ltd ポリペプチドおよびその製造法
US5824319A (en) * 1990-10-04 1998-10-20 Research Corporation Technologies, Inc. Varicella-zoster virus antigen
NL9100989A (nl) * 1991-06-07 1993-01-04 Stichting Centr Diergeneeskund Bovine herpesvirus type 1 deletiemutanten, daarop gebaseerde vaccins, diagnostische kits voor detectie van bovine herpesvirus type 1.

Also Published As

Publication number Publication date
JP3990445B2 (ja) 2007-10-10
CA2068654A1 (en) 1992-04-05
DE69132404T2 (de) 2001-02-15
DE69132404D1 (de) 2000-10-12
JPH05502595A (ja) 1993-05-13
WO1992006989A1 (en) 1992-04-30
CA2068654C (en) 2011-01-04
EP0504388B1 (en) 2000-09-06
EP0504388A4 (en) 1993-04-28
DK0504388T3 (da) 2000-12-27
EP0504388A1 (en) 1992-09-23
ATE196163T1 (de) 2000-09-15
US6180369B1 (en) 2001-01-30
KR920703614A (ko) 1992-12-18

Similar Documents

Publication Publication Date Title
McClain et al. An altered immune response to Epstein‐Barr nuclear antigen 1 in pediatric systemic lupus erythematosus
Powell et al. Type-specific protein in herpes simplex virus envelope reacts with neutralising antibody
ES2128362T3 (es) Fragmentos de proteinas de prion.
ES2072851T3 (es) Anticuerpos monoclonales para receptores fc para inmunoglobulina g en fagocitos mononucleares humanos; anticuerpos bifuncionales; celulas efectoras especificas de una diana; macrofagos con diana fijada; e inmunoensayos.
ES2110236T3 (es) Dispositivo mejorado destinado para dosificados inmunologicos quimioluminiscentes automaticos.
ES2142790T3 (es) Epitopos antigenicos presentes sobre iga unida a la membrana pero no secretada.
ATE41913T1 (de) Verstaerkte erdalkalialuminosilikatglaeser.
MX174568B (es) Material estructural resistente al fuego y metodo para fabricar el mismo
ES2130121T3 (es) Antigeno intra-acrosomico de esperma humano para uso en una vacuna anticonceptiva.
ATE48183T1 (de) Selektiv lichtdurchlaessige platte.
ES2150906T3 (es) Antigeno del virus varicella-zoster.
TR200102034T2 (tr) Anti kanser aşılaması için antikorların kullanılması
BR0005244A (pt) Uso de elementos constituìdos de um materialcomposto reforçado com fibra com matrizcerâmica
ES8205158A1 (es) Procedimiento para la fabricacion de un material laminar plastico reforzado con fibra de vidrio
LU91287I2 (fr) Vaccin zona (vivant) et ses dérivés pharmaceutiquement acceptables (ZOSTAVAXr)
PT964697E (pt) Aplicacoes terapeuticas de antigenios ou epitopos, associados com um processamento celular de peptidos deficiente, e.g. expressos em celulas rma-s transfectadas com um gene b7-1
Park et al. Measurement of antibodies to varicella-zoster virus using a virus-free fluorescent-antibody-to-membrane-antigen (FAMA) test
Cozzani et al. Patients with oral erosive and cutaneous lichen planus may have antibodies directed against the chronic ulcerative stomatitis protein antigen of 70-kDa
MX9102647A (es) Nueva proteina capaz de inducir una respuesta inmunoprotectora contra la infeccion causada por toxoplasma gondii y para clonar y expresar un gen que codifica a la proteina.
GB483342A (en) Improvements relating to light reflecting lenses for kerbs and edges of roadways
Mawas et al. Role of cellular antigens in humoral and cell-mediated immunity as measured in vitro
ATE39054T1 (de) Dns viren-vakzin.
GB453269A (en) Improvements in reflectors for roadside kerbs and like uses
夏林圻 et al. THE NEWEST TESTIMONY OF MAGMATIC ORIGIN OF SPILITE
Padilla et al. Varicella-zoster virus with a lost gE epitope: evidence for immunological pressure by the human antibody response

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 504388

Country of ref document: ES